In mid and south Essex, access to tirzepatide will initially be through Tier 3 weight management services only, with a rollout in primary care settings planned for later in 2025.
NHS Mid and South Essex ICB has published information on its website.
Access to tirzepatide for weight management in mid and south Essex – Mid and South Essex Integrated Care System
To support practices with patient enquiries, the below script is provided which can be added to practice websites or provided to reception teams when speaking to patients.
Further information about tirzepatide for primary care colleagues, including an FAQ, will be provided on the Primary Care Hub shortly.
Notice for practice websites/script for reception teams
Update on tirzepatide for weight management
On 23rd June 2025, it was announced that people living with obesity will be able to begin accessing tirzepatide (Mounjaro®) for weight loss purposes in primary care settings. However, the national roll out does not mean all people will be able to get a prescription for tirzepatide (Mounjaro®) on this day.
Weight management services are locally commissioned at an Integrated Care Board (ICB) level. In mid and south Essex, access to tirzepatide will initially be through specialist weight management services only. Access to tirzepatide (Mounjaro®) through primary care is not expected to start in mid and south Essex until later in 2025.
NHS Mid and South Essex ICB has provided information on tirzepatide on its website – Visit the website for more information.
